The European Commission negotiates Modern purchase of 80 million doses of its vaccine against the coronavirus - The European Commission is in talks with Moderna to acquire 80 million doses of its coronavirus vaccine, the US biotech company announced in a statement.
Moderna is developing a messenger RNA vaccine and was the first company to initiate human trials. He is currently completing Phase 3 with 30,000 volunteers, which he expects to finish in September, and believes his candidate will be ready for emergency marketing in the fall.
"The possible purchase agreement with the European Commission for 80 million doses provides an option for member states to purchase an additional 80 million doses for a total of up to 160 million doses," he adds.
European Commission negotiates Modern purchase
The agreement would form part of the European Union's efforts to negotiate with major pharmacists the vaccine Reserve in order to meet the demand in the member countries.
"We appreciate the European Commission's collaboration to help ensure that Europeans have access to a safe and effective vaccine, and we are proud that the European Commission has recognised the potential of our messenger RNA vaccine technology," writes Moderna CEO Stephen Bancel.
To date, no vaccine based on messenger RNA has reached the market. Should the de Moderna be successful, the company is scaling up its manufacturing capacity and assures that they will be able to produce about 500 million doses this year and 1,000 million by 2021.
On 17 June, the European Union launched its European vaccine strategy to ensure that everyone in the bloc has access to an inoculation. It has been allocated 2.050 million euros and recently the European Commission closed an agreement with AstraZeneca for 300 million doses that could be expanded with another 100 million.
It has also agreed with the French pharmaceutical company Sanofi the purchase of 300 vaccines if it manages to carry the candidate in development until the end of the clinical trials and has spoken with the German CureVac to guarantee 225 million doses.
End European Commission negotiates Modern purchase
This new technology could deliver drugs that are too viscous to be injected with conventional medical syringes
MIT researchers have developed a simple and cost-effective technology to administer potent drugs that are too viscous to be injected with conventional medical syringes, according to MIT News.
The technology allows injecting high-concentration drugs and other subcutaneous treatments and was developed as a solution for highly effective and extremely concentrated biopharmaceutical or biological products, which are usually diluted and injected intravenously.
"Drug manufacturers should focus on what they do best and formulate drugs, not get stuck by this injectability problem," said Kripa Varanasi, a professor of Mechanical Engineering at MIT.
The leaders of the Bill and Melinda Gates Foundation had a concern related to the problem of injectability. So they contacted Varanasi with the aim of providing high-concentration vaccines and biological therapies to people in developing countries who could not travel from remote areas to a medical environment, according to MIT News.
In addition, technology can be harnessed in developed countries.
In this sense, as a result of the current pandemic, staying at home and self-administering subcutaneous medications to treat diseases such as cancer or autoimmune disorders can be quite beneficial.
"Self-administration of medicines or vaccines can help democratize access to health care," Varanasi explained.
The new system makes it possible to inject high-concentration drug formulations subcutaneously by reducing the required injection force.
For this, the viscous fluid that is injected is surrounded by a lubricating fluid, which facilitates the flow of the fluid through the needle.
Thanks to the lubricant, only one seventh of the injection force is required for the highest viscosity tested.
"No matter how viscous your medication is, you can inject it, and this is what made this approach very attractive to us," commented Vishnu Jayaprakash, a graduate student in MIT's Department of Mechanical Engineering who is the first author of the work.
Until now, subcutaneous administration of Medicinal Products has involved impractical and costly methods due to their high viscosity.
Usually, drugs of this type are diluted and administered intravenously, which requires a visit to a hospital or a doctor's office.
In addition, they are prone to splash contamination.
The device consists of a syringe with 2 barrels, one inside the other, with the inner tube that supplies the viscous fluid of the drug and the surrounding tube that provides a thin layer of lubricant to the medication when it enters the needle, as explained by MIT News.
And, according to Pramod Bonde, assistant professor of surgery at Yale School of Medicine, the technique could revolutionize the field of Medicine.
"This innovative technology has the potential to have a fundamental and far-reaching impact on the way medicines are delivered to the body," said Bonde.
On the other hand, technology could make a difference in the search for possible vaccines and treatments for COVID-19.